| abstract |
Eyedrop solution for the treatment of ocular hypertension characterized by the fact of consisting essentially of the combination of the following components expressed in percent by weight:n from 0.01 to 2.0% of at least one hydrosoluble salt of ketanserin, for example ketanserin tartrate; optionally, from 0.01 to 10% of a substance that may stabilize the lacrimal film, selected preferably from the group comprising hydroxymethylcellulose, polyacrylic acid, propylenglycol, anhydrous dextrose and their combinations; optionally, from 0.001 to 0.01% of a preservative, for example benzalkonium chloride; optionally, a buffer system for maintaining the pH between the range 4.5 - 6.0, for example 0.1 - 1.0% of monopotassium phosphate and 0.1 - 1.5% of disodium phosphate; optionally, a colorimetric indicator that is biocompatible and pharmaceutically acceptable for revealing departures in the pH from the range 4.5 - 6.0; optionally, a solution that is isotonic with the osmotic pressure of the lacrimal fluid; optionally, at least one substance selected from the group comprising beta blockers, pilocarpine, alpha blockers, inhibitors of carbonic anhydrase, inhibitors of angiotensin converting enzyme and their combinations, the balance up to 100% being water. |